453 related articles for article (PubMed ID: 7595712)
1. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
Loehrer PJ; Ansari R; Gonin R; Monaco F; Fisher W; Sandler A; Einhorn LH
J Clin Oncol; 1995 Oct; 13(10):2594-9. PubMed ID: 7595712
[TBL] [Abstract][Full Text] [Related]
2. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
Hanna NH; Sandier AB; Loehrer PJ; Ansari R; Jung SH; Lane K; Einhorn LH
Ann Oncol; 2002 Jan; 13(1):95-102. PubMed ID: 11863118
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
[TBL] [Abstract][Full Text] [Related]
4. Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
Einhorn LH; Loehrer PJ
Semin Oncol; 1995 Feb; 22(1 Suppl 2):28-31. PubMed ID: 7846539
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
6. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
7. Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study.
Hanna N; Ansari R; Fisher W; Shen J; Jung SH; Sandler A
Lung Cancer; 2002 Mar; 35(3):293-7. PubMed ID: 11844604
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
Woo IS; Park YS; Kwon SH; Park YL; Lee JA; Park MJ; Hyun IG; Jung KS; Bae HS; Oh DH; Kim WS; Park K; Park CH; Kim HJ; Ahn YC
Jpn J Clin Oncol; 2000 Dec; 30(12):542-6. PubMed ID: 11210163
[TBL] [Abstract][Full Text] [Related]
10. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
11. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
12. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Glisson B; Scott C; Komaki R; Movsas B; Wagner H
J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
[TBL] [Abstract][Full Text] [Related]
15. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
[TBL] [Abstract][Full Text] [Related]
17. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer.
Loehrer PJ; Rynard S; Ansari R; Songer J; Pennington K; Einhorn L
Cancer; 1992 Feb; 69(3):669-73. PubMed ID: 1309677
[TBL] [Abstract][Full Text] [Related]
18. Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer.
Wu MF; Perng RP; Chen YM; Liu JM; Yang SL; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Aug; 60(2):67-73. PubMed ID: 9360330
[TBL] [Abstract][Full Text] [Related]
19. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
Iwasaki Y; Nagata K; Nakanishi M; Natuhara A; Kubota Y; Ueda M; Arimoto T; Hara H
Chest; 2005 Oct; 128(4):2268-73. PubMed ID: 16236883
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
